Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HT-001 (aprepitant) is a Neurokinin 1 receptor inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of skin toxicities associated with EGFR Inhibitors.
Lead Product(s): Aprepitant
Therapeutic Area: Dermatology Product Name: HT-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
HT-001 (aprepitant) is an investigational topical therapeutic product. Currently it is being evaluated in phase 2 clinical trials for the treatment of rash and skin disorders associated with EGFR inhibitor therapy.
Lead Product(s): Aprepitant
Therapeutic Area: Dermatology Product Name: HT-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting, which is investigated for the treatment of advance Cancer Patients.
Lead Product(s): HT-KIT
Therapeutic Area: Immunology Product Name: HT-KIT
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting, which is investigated for the treatment of advance Cancer Patients.
Lead Product(s): HT-KIT
Therapeutic Area: Immunology Product Name: HT-KIT
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting, which is investigated for the treatment of advance systemic mastocytosis.
Lead Product(s): HT-KIT
Therapeutic Area: Immunology Product Name: HT-KIT
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of atopic dermatitis. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.
Lead Product(s): Gentamicin Sulfate
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
HT-ALZ is an orally administered drug that reduce the concentration of Aβ in the brain interstitial fluid, using an established Alzheimer's Disease mouse model (aged APP/PS1+/- mice).
Lead Product(s): HT-ALZ
Therapeutic Area: Neurology Product Name: HT-ALZ
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
HT-001 (aprepitant) is a investigational therapeutic product for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of multiple cancer.
Lead Product(s): Aprepitant
Therapeutic Area: Dermatology Product Name: HT-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
HT-001 (aprepitant) is a investigational therapeutic product for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of multiple cancer.
Lead Product(s): Aprepitant
Therapeutic Area: Dermatology Product Name: HT-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
HT-001 (aprepitant) is a investigational therapeutic product for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of multiple cancer.
Lead Product(s): Aprepitant
Therapeutic Area: Dermatology Product Name: HT-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023